

Special Issue

Advancing Vaccine Strategies Against Viral Hemorrhagic Fevers: Innovation and Challenges

Message from the Guest Editors

Viral Hemorrhagic Fevers (VHFs) represent a significant global health threat, causing severe outbreaks with high morbidity and mortality rates. Infections like Ebola, Marburg, Lassa fever, Crimean–Congo hemorrhagic fever, and Rift Valley fever remain major public health concerns worldwide, with most of them listed by WHO as priority pathogens. Despite ongoing research efforts, effective and widely accessible vaccines remain limited for many of these diseases, and thus development of both preventive and therapeutic vaccines is a top priority for global health security in the years to come. This collection aims to collate cutting-edge research and comprehensive reviews on the latest developments in vaccine design, immunological responses, and clinical trials, as well as animal trials and real-world implementation strategies for VHFs. It includes, but is not limited to the following:

- Novel vaccine platforms for VHFs
- Advances in antigen design and immunogenicity studies
- Preclinical and clinical evaluation of VHF vaccines
- Immune correlates of protection and long-term immunity
- Challenges in vaccine deployment, accessibility, and global distribution
- Therapeutic vaccines

Guest Editors

Dr. Massimo Spedicato

Istituto Zooprofilattico Sperimentale dell'Abruzzo e del Molise G. Caporale, 64100 Teramo, Italy

Dr. Stuart David Dowall

Virology & Pathogenesis group, UK Health Security Agency (UK), Porton Down, Salisbury SP4 0JG, UK

Deadline for manuscript submissions

31 March 2026



Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



mdpi.com/si/235255

Vaccines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
vaccines@mdpi.com

[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)





Vaccines

an Open Access Journal
by MDPI

Impact Factor 3.4
CiteScore 9.9
Indexed in PubMed



[mdpi.com/journal/
vaccines](https://mdpi.com/journal/vaccines)



About the Journal

Message from the Editor-in-Chief

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

Editor-in-Chief

Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine,
University of Georgia, Athens, GA 30602-7387, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPIus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Medicine, Research and Experimental) /
CiteScore - Q1 (Pharmacology (medical))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 19.6 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the first half of 2025).